All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubGVhD HubLymphoma HubMDS HubMPN HubMultiple Myeloma

Editorial theme │ Induction therapy for AML: Recent progress

Apr 20, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in AML

Efforts to improve induction therapy outcomes in patients with acute myeloid leukemia (AML) have proven difficult. Broader understanding of the molecular pathophysiology of the disease has provided opportunities to develop targeted therapies for patients who are ineligible for intensive chemotherapy, to ultimately improve survival outcomes when added to intensive chemotherapeutic backbones.

In this editorial theme on induction therapy, we summarize recent data investigating targeted agents for intensive induction therapy, and real-world survival outcomes for patients ineligible for intensive chemotherapy.

Intensive chemotherapy

The therapeutic mainstay for intensive chemotherapy in AML is the ‘3 + 7 regimen’ (3 days of daunorubicin + 7 days of cytarabine) with variations to the chemotherapeutic backbone.1 Recently, improved understanding of genetic and cytogenetic abnormalities that may impair response to chemotherapy alone has led to the development and approval of targeted therapies.

FLT3 inhibitors

For patients with internal tandem duplications (ITD) or tyrosine kinase domain (TKD) point mutations of the fms-related tyrosine kinase 3 gene (FLT3), addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy has shown prolonged survival.2 The pivotal phase III RATIFY trial (NCT00651261) demonstrated significant improvements in median overall survival (OS) and event-free survival (EFS) with the addition of midostaurin to standard chemotherapeutic backbone (induction therapy with daunorubicin plus cytarabine and consolidation therapy with high-dose cytarabine). The benefit of midostaurin was consistent across all FLT3 subtypes. Further research is ongoing to evaluate the efficacy of more specific FLT3 inhibitors, such as quizartinib and gilteritinib, or another nonspecific FLT3 inhibitor, sorafenib.2

Gemtuzumab ozogamicin

Gemtuzumab ozogamicin (GO), an anti-CD33 antibody-drug conjugate, was approved in 2017 by the U.S. Food and Drug Administration (FDA) for adult patients with newly diagnosed de novo CD33-positive AML. The best way to use GO in induction therapy is uncertain, however. Recent data indicate that patients with newly diagnosed AML benefit from fractionated doses of GO when combined with cladribine, high-dose cytarabine, granulocyte colony-stimulating factor (G-CSF) and mitoxantrone (CLAG-M).3

IDH1 and IDH2 inhibitors

In patients with newly diagnosed AML, the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosidenib, and IDH2 inhibitor enasidenib, have demonstrated complete response (CR) rates of >70% in a phase I trial when combined with intensive induction and consolidation chemotherapy. IDH inhibitors were well tolerated, and no deaths related to treatment were observed.4

Venetoclax

The benefit of the BCL-2 inhibitor venetoclax has been investigated with intensive chemotherapy regimens. For example, a recent phase II single arm study demonstrated durable CR rates in younger patients (<65 years old) with newly-diagnosed AML, treated with venetoclax in combination with a high intensive chemotherapy regimen of cladribine with higher dose cytarabine and idarubicin.5

Eprenetapopt (APR-246)

TP53 mutations are consistently associated with poor prognosis and reduced OS. Eprenetapopt is a p53 reactivator with orphan drug designation by the FDA in TP53-mutant myelodysplastic syndromes (MDS). In a recent phase II trial, eprenetapopt with azacitidine demonstrated that median OS was significantly improved in a combined cohort of patients with TP53-mutant MDS or oligoblastic AML, with a median OS of 11.8 months in all patients.6

Overall, there has been a rapid expansion of clinical trials for targeted agents in newly diagnosed AML in recent years; combinations of targeted therapies with intensive chemotherapy or alone are still to be explored.

Non-intensive induction therapy

The use of non-intensive induction therapy, namely, low-dose cytarabine (LDAC), hypomethylating agents (HMAs), or best supportive care (BSC), is the standard for patients unfit for intensive chemotherapy. Clinical trial data have demonstrated consistent poor OS across these therapies in older patients with AML unable to tolerate intensive chemotherapy. A recent registry analysis provided real-world evidence that patients receiving intensive induction have greater remission rates and better OS compared with patients who receive non-intensive induction.7

Further analysis of non-intensive chemotherapy outcomes was presented in a large noninterventional retrospective study at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition (ASH 2020), including 1,762 patients receiving HMA, BSC, or LDAC between January 2015 and December 2018.8

Results8

Patient characteristics are summarized in Table 1.

Table 1. Patient characteristics*

Characteristic

N = 1,762

Therapy, %

              BSC only

26

              HMA

62

              LDAC

15

              Other systemic therapies

23

Male, %

57

Median age, years (range)

75 (20–89)

Secondary AML, %

32

ECOG-PS

              0–1

38

              ≥2

43

              Unknown

19

Molecular mutation, %

17

Cytogenetic risk, %

              Favorable

12

              Intermediate

32

              Poor

25

              Unknown

30

AML, acute myeloid leukemia; BSC, best supportive care; ECOG-PS, Eastern Cooperative Oncology Group performance status; HMA, hypomethylating agents; LDAC, low-dose cytarabine.
*Adapted from Kondo et al.8

Median progression-free survival (PFS) in the overall population was 4.7 months. The median time-to-treatment failure (TTF), OS, and PFS by therapy are summarized in Figure 2.

Figure 2. Median TTF, PFS, and OS*

BSC, best supportive care; HMA, hypomethylating agent; LDAC, low-dose cytarabine; OS, overall survival; PFS, progression-free survival; TTF, time-to-treatment failure.
*Adapted from Kondo et al.8

 

The complete remission/complete remission with incomplete hematologic recovery rate was 19%, 27%, and 21% with HMA, LDAC, and other systemic therapies, respectively. The median time to best response was 115, 55, and 41 days, respectively.

In summary, real-world data gathered in that study8 was in line with clinical trials demonstrating poor OS for patients with AML who are ineligible for intensive chemotherapy. For that patient population, the development of novel agents or combination therapies remains an unmet clinical need.

Further approaches for patients ineligible for intensive chemotherapy

Venetoclax

A notable change to induction formulations for patients ineligible for intensive chemotherapy is the addition of venetoclax to azacitidine, decitabine, and LDAC. The FDA granted these combinations approval in 2020 following results of the pivotal phase III VIALE-A (NCT02993523) and VIALE-C (NCT03069352) trials, demonstrating a significant reduction in the risk of death, increased median OS and CR rate when compared to azacitidine or LDAC alone.9

Real-world comparisons of HMA + venetoclax have demonstrated comparable OS and complete remission/complete remission with incomplete hematologic recovery with liposomal formulation of daunorubicin and cytarabine (CPX-351), given to older fit patients. CPX-351 was associated with higher rate of adverse events such as febrile neutropenia, infection, and increased hospital stay.10 Despite study limitations, the survival outcomes of a more tolerable treatment for unfit patients are encouraging to help guide treatment options when it is difficult to define patient fitness. Replication of prospective trials will be needed.

What does real-world data tell us about frontline therapy with CPX-351 vs venetoclax + azacitidine?

However, improved response rates were not reached in patients with poor-risk cytogenetics who harbor TP53 mutations, with recent data presented at the 63rd ASH Annual Meeting and Exposition (ASH 2021) revealing no significant difference in the median duration of response (DoR) in patients with TP53mut treated with venetoclax + azacitidine (6.54 months) versus azacitidine alone (6.7 months).11

FLT3 inhibitors

The addition of FLT3 inhibitors to low-intensity chemotherapy is still a clinical approach in its infancy. In a phase I/II trial, including a newly diagnosed FLT3-ITD-mutated AML cohort, patients were treated with quizartinib, a FLT3 inhibitor, in combination with venetoclax and decitabine. All patients achieved a response. In a median follow-up duration of 16 months, the median OS was 14.5 months.12

Conclusion

While challenges around improved survival remain, the outlook of non-intensive induction therapy for AML has evolved in recent years with the approval of targeted agents, particularly the addition of venetoclax to HMAs and LDAC. Growing clinical data has demonstrated improved outcomes when certain targeted therapies are added to intensive chemotherapeutic backbones, thus, potentially leading to improved individualization of induction therapy strategies in the future.

  1. Kantarjian H, Kadia T, DiNardo C, et al. Acute myeloid leukemia: Current progress and future directions. Blood Cancer J. 2021; 11(41). DOI. 1038/s41408-021-00425-3
  2. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 N Engl J Med. 2017;377(5):454-464. DOI: 10.1056/NEJMoa1614359
  3. Godwin CD, Othus M, Percival M-E, et al. A phase 1/2 trial of cladribine, high-dose cytarabine, G-CSF, and dose-escalated mitoxantrone (CLAG-M) plus gemtuzumab ozogamicin in adults with newly-diagnosed acute myeloid leukemia (AML) or other high-grade myeloid neoplasm. Oral Abstract #34. 63rd ASH Annual Meeting and Exposition; Dec 11, 2021; Atlanta, US.
  4. Stein EM, DiNardo CD, Fathi AT, et al. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021;137(13):1792-1803. DOI: 1182/blood.2020007233
  5. Kadia TM, Reville PK, Borthakur G, et al. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: A cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021;8(8):e552-e561. DOI: 1016/S2352-3026(21)00192-7
  6. Sallman DA, Komrokji RS, DeZern AE, et al. Long term follow-up and combined phase 2 results of eprenetapopt (APR-246) and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML). Oral Abstract #246. 63rd ASH Annual Meeting and Exposition; Dec 11, 2021; Atlanta, US.
  7. Roboz G, Abedi M, Thompson MA, et al. Treatment patterns and survival outcomes of patients with acute myeloid leukemia who achieved remission in the Connect® Myeloid Disease Registry. Oral abstract #279. 63rd ASH Annual Meeting and Exposition; Dec 12, 2021; Atlanta, US.
  8. Kondo T, Sanford D, Tomuleasa C, et al. Real-world treatment patterns and clinical outcomes in unfit patients with AML receiving first-line systemic treatment or best supportive care (CURRENT): Final analysis. Oral abstract #1914. 62nd ASH Annual Meeting and Exposition; Dec 6, 2020; San Diego, US.
  9. DiNardo CJ, Jonas BA, Pullarkat V, et al. A randomized, double-blind, placebo-controlled study of venetoclax with azacitidine vs azacitidine in treatment-naïve patients with acute myeloid leukemia ineligible for intensive therapy-VIALE-A. Oral presentation #303390. 25th EHA Annual Congress; June 14, 2020; Virtual.
  10. Grenet J, Jain AG, Burkart M, et al. Comparing outcomes between liposomal daunorubicin/cytarabine (CPX-351) and HMA + venetoclax as frontline therapy in acute myeloid leukemia. Oral abstract #32. 63rd ASH Annual Meeting and Exposition; Dec 11, 2021; Atlanta, US.
  11. Pollyea DA, Pratz KW, Wei AH, et al. Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax combined with hypomethylating agents. Oral abstract #224. 63rd ASH Annual Meeting and Exposition; December 11, 2021; Atlanta, US.
  12. Yilmaz M, Muftuoglu M, Kantarjian H, et al. Quizartinib (Quiz) with decitabine (DAC) and venetoclax (VEN) is highly active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML) – RAS/MAPK mutations continue to drive primary and secondary resistance. Oral abstract #370. 63rd ASH Annual Meeting and Exposition; Dec 12, 2021; Atlanta, US.

Share: